Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 165

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 165
---
 there could be an increase in third -partyclaims to patent rights over correlations between patient genetic data and its interpretation and such third parties may assert that our business practices infringe some of those resulting patent rights. There have also been several cases involving “gene patents” and diagnostic claims that have been considered by the U.S. Supreme Court that have affected the legal concept of subject matter eligibility by seemingly narrowing the scope of the statute defining patentable inventions. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. Such changes in existing law and practice could negatively impact our business, financial condition, results of operations and growth prospects. Third parties may assert that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information or misappropriated trade secrets. We employ, and expect to employ in the future, individuals who were previously employed at universities or biometric solution, genetic testing, diagnostic or other healthcare companies, including our competitors or potential competitors. Although we try to ensure that our employees and consultants do not use the proprietary information or know -howof others in their work for us, we may be subject to claims that we or our employees or consultants have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of a former employer or other third parties. Further, we may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing our intellectual property. Litigation may be necessary to defend against such claims. If we fail in defending against any such claims, we could be subject to monetary damages and the loss of valuable intellectual property rights or personnel. Even if we are successful in defending against any such claim, litigation could result in substantial costs, distract management and other employees and damage our reputation. Risks Related to Operating in Argentina The Business Combination is subject to antitrust regulation in Argentina. The Business Combination is subject to review under Argentine antitrust and competition laws, including Law No. 27,442 ( Ley de Defensa de la Competencia). We will be required, within seven days of the Closing, to file notice of the Closing with applicable antitrust authorities in Argentina (however, regulatory changes may take place in the near future that may require notification prior to the Closing), and to provide upon request any additional information required by such